Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04679909 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
A Phase 1 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT04679909: Completed Phase 1 study, sponsored by Altimmune.
NCT04679909 is a Phase 1 study that has completed, run by Altimmune. The registered enrollment target is 92 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04679909, a Phase 1 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
Primary Outcome
Counts and percentages of subjects with local and systemic events
Interventions
- OTHER Placebo
- BIOLOGICAL AdCOVID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 1 |
What the finished NCT04679909 record still lists
NCT04679909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04679909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04679909 about?
NCT04679909 is a clinical study titled "Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)". A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
What is the current status of trial NCT04679909?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2021-02-25. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT04679909?
The interventions under investigation include: Placebo (OTHER), AdCOVID (BIOLOGICAL).
Who is sponsoring clinical trial NCT04679909?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04679909's enrollment target sits among peer trials
92 625th of 2000 higher than 1,375 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI